Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
European Surgery
Erschienen in:

01.08.2016 | review

Large bowel cancer in the setting of inflammatory bowel disease

Features and management with a focus on rectal cancer

verfasst von: Gianluca Pellino, MD, Rosa Marcellinaro, MD, Guido Sciaudone, MD, Alfonso Reginelli, MD PhD, Pasquale Esposito, MD, Gabriele Riegler, MD, Silvestro Canonico, MD, Vincenzo Villanacci, MD, Francesco Selvaggi, MD

Erschienen in: European Surgery | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Summary

Background

Inflammatory bowel diseases (IBDs) are a well-known risk factor for the development of colorectal cancer (CRC). This risk relates to different aspects of the disease, such as the duration, activity, and extension, and tends to increase in the presence of associated conditions, such as family history of CRC or some extra-intestinal manifestations. Rectal cancer (RC) in IBD has been poorly investigated.

Methods

We reviewed the scientific literature for data on the features and management of RC in the setting of IBD. Here, we provide a practical insight into the diagnosis and management of the condition.

Results

Several genetic and environmental factors promote the development of CRC, including alterations of intestinal microflora and mutations in the genes responsible for the cell cycle and for DNA mismatch repair. Dysplasia is the main evidence of a clear conversion of normal epithelium to cancer. Dysplasia is often multifocal, in contrast to sporadic CRC, which explains the tendency toward the development of synchronous and metachronous CRC in patients with IBD. Other conditions that need attention are strictures, for which the threshold for surgery must be low. Treatment of RC in patients with IBD follows the same oncologic criteria as non-IBD-related RC, but patients are often diagnosed at more advanced stages, suggesting that this is frequently overlooked. This is ultimately associated with poorer outcomes in IBD patients.

Conclusion

There is a pressing need for more data on IBD-related RC. Implementing knowledge will result in optimization of survival for these patients.
Vorheriger Artikel Current strategies for preoperative conditioning of the liver to expand criteria for resectability of hepatic metastases
Nächster Artikel Advances in diagnosing GERD
Literatur
1.
2.
Jess T, Loftus EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, Schleck CD, Tremaine WJ, Melton LJ, Munkholm P, et al. Risk of intestinal cancer in inflammatory bowel disease:a population-based study from olmsted county,Minnesota. Gastroenterology. 2006;130:1039–46.PubMedCrossRef
3.
Sebastian S, Hernández V, Myrelid P, Kariv R, Tsianos E, Toruner M, Marti-Gallostra M, Spinelli A, Meulen-de Jong AE van der, Yuksel ES, Gasche C, Ardizzone S, Danese S. Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I). J Crohns Colitis. 2014;8(1):5–18.PubMedCrossRef
4.
Egan L, D’Inca R, Jess T, Pellino G, Carbonnel F, Bokemeyer B, Harbord M, Nunes P, Van der Woude J, Selvaggi F, Triantafillidis J. Non-colorectal intestinal tract carcinomas in inflammatory bowel disease: results of the 3rd ECCO Pathogenesis Scientific Workshop (II). J Crohns Colitis. 2014;8(1):19–30.PubMedCrossRef
5.
Selvaggi F, Pellino G, Canonico S, Sciaudone G. Systematic review of cuff and pouch cancer in patients with ileal pelvic pouch for ulcerative colitis. Inflamm Bowel Dis. 2014;20(7):1296–308.PubMedCrossRef
6.
Gyde SN, Prior O, Allan RN, et al. Colorectal cancer in ulcerative colitis:a cohort study of primary referrals from three centres. Gut. 1988;29:206–17.PubMedPubMedCentralCrossRef
7.
Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment Pharmacol Ther. 2004;20:24–30.PubMedCrossRef
8.
Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A. Thirty-year analysis ofa colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology. 2006;130:1030–8.PubMedCrossRef
9.
Lakatos L, Mester G, Erdelyi Z, David G, Pandur T, Balogh M, Fischer S, Vargha P, Lakatos PL. Risk factors for ulcerative colitis-associated colorectal cancer ina Hungarian cohort of patients with ulcerative colitis: results ofa population-based study. Inflamm Bowel Dis. 2006;12:205–11.PubMedCrossRef
10.
11.
Kim BJ, Yang SK, Kim JS, Jeen YT, Choi H, Han DS, Kim HJ, Kim WH, Kim JY, Chang DK. Trends of ulcerative colitis-associated colorectal cancer in Korea: A KASID study. J Gastroenterol Hepatol. 2009;24:667–71.PubMedCrossRef
12.
Söderlund S, Brandt L, Lapidus A, Karlén P, Broström O, Löfberg R, Ekbom A, Askling J. Decreasing time-trends of colorectal cancer ina large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009;136:1561–1157, quiz 1818–9.PubMedCrossRef
13.
Jess T, Horváth-Puhó E, Fallingborg J, Rasmussen HH, Jacobsen BA. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment:a Danish population-based cohort study. Am J Gastroenterol. 2013;108:1869–76.PubMedCrossRef
14.
15.
Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228–33.PubMedCrossRef
16.
Gupta RB, Harpaz N, Itzkowitz S, Hossain S, Matula S, Kornbluth A, Bodian C, Ullman T. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099–105.PubMedPubMedCentralCrossRef
17.
Smith MP, Loe RH. Sclerosing cholangitis. Review of recent case reports and associated diseases and four new cases. Am J Surg. 1965;110:239–46.PubMed
18.
Askling J, Dickman PW, Karlén P, Broström O, Lapidus A, Löfberg R, Ekbom A. Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease:a population-based cohort study. Lancet. 2001;357:262–6.PubMedCrossRef
19.
Velayos FS, Loftus EV, Jess T, Harmsen WS, Bida J, Zinsmeister AR, Tremaine WJ, Sandborn WJ. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006;130:1941–9.PubMedCrossRef
20.
Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet. 1990;336:357–9.PubMedCrossRef
21.
Jess T, Winther KV, Munkholm P, Langholz E, Binder V. Intestinal and extra-intestinal cancer in Crohn’s disease: follow-up of a population-based cohort in Copenhagen County, Denmark. Aliment Pharmacol Ther. 2004;19:287–93.
22.
Jess T, Gamborg M, Matzen P, Munkholm P, Sørensen TI. Increased risk of intestinal cancer in Crohn’s disease:a meta-analysis of population-based cohort studies. Am J Gastroenterol. 2005;100:2724–9.PubMedCrossRef
23.
Friedman S, Rubin PH, Bodian C, Harpaz N, Present DH. Screening and surveillance colonoscopy in chronic Crohn’s colitis: results ofa surveillance program spanning 25 years. Clin Gastroenterol Hepatol. 2008;6:993–8.PubMedCrossRef
24.
Canavan C, Abrams KR, Meta-analysis MJ. colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther. 2006;23:1097–104.PubMedCrossRef
25.
Roon AC von, Reese G, Teare J, Constantinides V, Darzi AW, Tekkis PP. The risk of cancer in patients with Crohn’s disease. Dis Colon Rectum. 2007;50:839–55.CrossRef
26.
Laukoetter MG, Mennigen R, Hannig CM, et al. Intestinal cancer risk in Crohn’s disease:a meta-analysis. J Gastrointest Surg. 2011;15:576–83.PubMedCrossRef
27.
Selvaggi F, Pellino G. Pouch-related fistula and intraoperative tricks to prevent it. Tech Coloproctol. 2015;19:63–7.PubMedCrossRef
28.
Söderlund S, Granath F, Broström O, Karlén P, Löfberg R, Ekbom A, et al. Inflammatory bowel disease confersa lower risk of colorectal cancer to females than males. Gastroenterology. 2010;138((5):1697–703.PubMedCrossRef
29.
Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn’s disease:a comparison of the colorectal cancer risk in extensive colitis. Gut. 1994;35:1590–2.PubMedPubMedCentralCrossRef
30.
Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther. 2006;23:1097–104.PubMedCrossRef
31.
Stahl TJ, Schoetz DJ, Roberts PL, et al. Crohn’s disease and carcinoma: Increasing justification for surveillance? Dis Colon Rectum. 1992;35:850–6.PubMedCrossRef
32.
Greenstein AJ, Sachar D, Pucillo A, Kreel I, Geller S, Janowitz HD, Aufses A Jr. Cancer in Crohn’s disease after diversionary surgery. A report of seven carcinomas occurring in excluded bowel. Am J Surg. 1978;135:86–90.PubMed
33.
Connell WR, Sheffield JP, Kamm MA, Ritchie JK, Hawley PR, Lennard-Jones JE. Lower gastrointestinal malignancy in Crohn’s disease. Gut. 1994;35:347–52.PubMedPubMedCentralCrossRef
34.
Lovasz BD, Lakatos L, Golovics PA, David G, Pandur T, Erdelyi Z, et al. Risk of colorectal cancer in Crohn’s disease patients with colonic involvement and stenosing disease in a population-based cohort from Hungary. J Gastrointestin Liver Dis. 2013;22(3):265–8.PubMed
35.
Hamilton SR. Colorectal carcinoma in patients with Crohn’s disease. Gastroenterology. 1985;89:398–407.PubMedCrossRef
36.
Triantafillidis JK, Nasioulas G, Kosmidis PA. Colorectal cancer and inflammatory bowel disease: epidemiology, risk factors, mechanisms of carcinogenesis and prevention strategies. Anticancer Res. 2009;29:2727–37.PubMed
37.
38.
Green S, Stock RG, Greenstein AJ. Rectal cancer and inflammatory bowel disease: natural history and implication for radiation therapy. Int J Radiol Oncol Biol Phys. 1999;44:835–40.CrossRef
39.
Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology. 2011;140:1807–16.PubMedCrossRef
40.
41.
Befrits R, Hammarberg C, Rubio C, Jaramillo E, Tribukait B. DNA aneuploidy and histologic dysplasia in long-standing ulcerative colitis. A 10-year follow-up study. Dis Colon Rectum. 1994;37:313–9, discussion 319-320.PubMedCrossRef
42.
Willenbucher RF, Zelman SJ, Ferrell LD, Moore DH, Waldman FM. Chromosomal alterations in ulcerative colitis-related neoplastic progression. Gastroenterology. 1997;113:791–801.PubMedCrossRef
43.
Lyda MH, Noffsinger A, Belli J, et al. Micro satellite instability and k‑ras mutations in patients with ulcerative colitis. Hum Pathol. 2000;31(6):655–71.CrossRef
44.
Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 2004;287(1):G7–G17.PubMedCrossRef
45.
46.
Lakatos PL, Lakatos L. Risk for colorectal cancer in ulcerative colitis: changes, causes and management strategies. World J Gastroenterol. 2008;14:3937–47.PubMedPubMedCentralCrossRef
47.
Itzkowitz S. Colon carcinogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice. J Clin Gastroenterol. 2003;36:70–4, discussion S94–96.CrossRef
48.
Leedham SJ, Graham TA, Oukrif D, McDonald SA, Rodriguez-Justo M, Harrison RF, et al. Clonality, founder mutations, and field cancerization in human ulcerative colitis-associated neoplasia. Gastroenterology. 2009;36(2):542–50.CrossRef
49.
Fogt F, Vortemeyer AO, Goldman H, Giordano TJ, Merino MJ, Zhuang Z. Comparison of genetic alterations in colonic adenoma and ulcerative colitis-associated dysplasia and carcinoma. Hum Pathol. 1998;29(2):131–6.PubMedCrossRef
50.
Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, et al. Increased p53 mutation load in noncancerous colon tissue from ulcerative colitis:a cancer prone-chronic inflammatory disease. Cancer Res. 2000;60(13):3333–7.PubMed
51.
Romano M, Cuomo A, Tuccillo C, Salerno R, Rocco A, Staibano S, Mascolo M, Sciaudone G, Mucherino C, Giuliani A, Riegler G, Nardone G, Del Vecchio BC, Selvaggi F. Vascular endothelial growth factor and cyclooxygenase-2 are overexpressed in ileal pouch-anal anastomosis. Dis Colon Rectum. 2007;50(5):650–9.PubMedCrossRef
52.
Svrcek M, El-Bchiri J, Chalastanis A, Capel E, Dumont S, Buhard O, Oliveira C, Seruca R, Bossard C, Mosnier JF, et al. Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability. J Clin Oncol. 2007;25:4231–8.PubMedCrossRef
53.
Schulmann K, Mori Y, Croog V, Yin J, Olaru A, Sterian A, et al. Molecular phenotype of inflammatory bowel disease-associated neoplasm with microsatellite instability. Gastroenterology. 2005;129(1):74–85.PubMedCrossRef
54.
Issa JP, Ahuja N, Toyota M, Bronner MP, Brentnall TA. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001;61(9):3573–7.PubMed
55.
Fleisher AS, Esteller M, Harpaz N, Leytin A, Rashid A, Xu Y, et al. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesion is associated with hypermethylation and diminished expression of DNA mismatchrepair gene, hMLH1. Cancer Res. 2000;60(17):4864–8.PubMed
56.
Hsieh CJ, Klump B, Holzmann K, Borchard F, Gregor M, Porschen R. Hypermethylation of the p16INK4a promoter in colectomy specimens of patients with long-standing and extensive ulcerative colitis. Cancer Res. 1998;58:3942–5.PubMed
57.
Azer SA. Overview of molecular pathways in inflammatory bowel disease associated with colorectal cancer development. Eur J Gastroenterol Hepatol. 2013;25:271–81.PubMedCrossRef
58.
Elzagheid A, Emaetig F, Alkikhia L, Buhmeida A, Syrjänen K, El-Faitori O, Latto M, Collan Y, Pyrhönen S. High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer. Anticancer Res. 2013;33:3137–43.PubMed
59.
Marnett LJ, DuBois RN. COX-2:a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002;42:55–80.PubMedCrossRef
60.
Atreya R, Mudter J, Finotto S, Müllberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signalling suppresses T‑cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med. 2000;6:583–8.PubMedCrossRef
61.
McLoughlin RM, Witowski J, Robson RL, Wilkinson TS, Hurst SM, Williams AS, et al. Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest. 2003;112:598–607.PubMedPubMedCentralCrossRef
62.
Li Y, Haar C de, Chen M, Deuring J, Gerrits MM, Smits R, et al. Disease-related expression of the IL6/STAT3/SOCS3 signalling pathway in ulcerative colitis and ulcerative colitis-related carcinogenesis. Gut. 2010;59(2):227–32.PubMedCrossRef
63.
Glocker EO, Kotlarz D, Boztung K, Gertz EM, Schäffer AA, Noyan F, et al. Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med. 2009;361:2033–45.PubMedPubMedCentralCrossRef
64.
Kimura H, Hokari R, Miura S, Shigematsu T, Hirokawa M, Akiba Y, Kurose I, Higuchi H, Fujimori H, Tsuzuki Y, et al. Increased expression of an inducible isoform of nitric oxide synthase and the formation of peroxynitrite in colonic mucosa of patients with active ulcerative colitis. Gut. 1998;42:180–7.PubMedPubMedCentralCrossRef
65.
Rachmilewitz D, Stamler JS, Bachwich D, Karmeli F, Ackerman Z, Podolsky DK. Enhanced colonic nitric oxide generation and nitric oxide synthase activity in ulcerative colitis and Crohn’s disease. Gut. 1995;36:718–23.PubMedPubMedCentralCrossRef
66.
Swidsinski A, Kilkin M, Kerjaschki D, Schreiber S, Ortner M, Weber j, et al. Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology. 1998;115(2):281–6.PubMedCrossRef
67.
Darfeuille-Michaud A, Neut C, Lederman E, Di Martino P, Desreumaux P, et al. Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn’s disease. Gastroenterology. 1998;115(6):1405–13.PubMedCrossRef
68.
Riddell RH. Premalignant and early malignant lesions in the gastrointestinal tract. Definitions, terminology, and problems. Am J Gastroenterol. 1996;91:864–72.PubMed
69.
Lim CH, Dixon MF, Vail A, Forman D, Lynch DA, Axon AT. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut. 2003;52:1127–32.PubMedPubMedCentralCrossRef
70.
Odze RD, Tomaszewski JE, Furth EE, Feldman MD, Diallo R, Poremba C, et al. Variability in the diagnosis of dysplasia in ulcerative colitis by dynamic telepathology. Oncol Rep. 2006;16:1123–9.PubMed
71.
Odze RD, Goldblum J, Noffsinger A, Alsaigh N, Rybicki LA, Fogt F. Interobserver variability in the diagnosis of ulcerative colitis-associated dysplasia by telepathology. Mod Pathol. 2002;15:379–86.PubMedCrossRef
72.
Rubin CE, Haggitt RC, Burmer GC, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology. 1992;103:1611–20.PubMedCrossRef
73.
Itzkowitz SH, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314–21.PubMedCrossRef
74.
Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet. 1994;343:71–4.PubMedCrossRef
75.
Farraye FA, Odze DR, Eaden J, Itzkowitz SH. AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:746–74.PubMedCrossRef
76.
Thomas T, Abrams KA, Robinson RJ, et al. Meta-analysis: cancer risk of low-grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther. 2007;25:657–68.PubMedCrossRef
77.
Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology. 2003;125:1311–9.PubMedCrossRef
78.
Choi CH, Ignjatovic-Wilson A, Askari A, Lee GH, Warusavitarne J, Moorghen M, Thomas-Gibson S, Saunders BP, Rutter MD, Graham TA. Hart AL Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer. Am J Gastroenterol. 2015;110:1461–71.PubMedPubMedCentralCrossRef
79.
Choi CH, Rutter MD, Askari A, Lee GH, Warusavitarne J, Moorghen M, Thomas-Gibson S, Saunders BP, Graham TA, Hart AL. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am J Gastroenterol. 2015;110:1022–34.PubMedPubMedCentralCrossRef
80.
Ullman TA, Croog V, Harpaz N, et al. Progression to colorectal neoplasia in ulcerative colitis: effect of 5‑aminosalicylic acid. Clin Gastroenterol Hepatol. 2008;6(11):1225–30.PubMedCrossRef
81.
Itzkowitz SH, Present DH. Consensus conference: Colorectal cancer screening and surveillance in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11:314–21.PubMedCrossRef
82.
Kelly JK, Gabos S. The pathogenesis of inflammatory polyps. Dis Colon Rectum. 1987;30:251–4.PubMedCrossRef
83.
Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, Williams CB, Price AB, Talbot IC, Forbes A. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813–6.PubMedPubMedCentralCrossRef
84.
Loftus EV, Harewood GC, Loftus CG, Tremaine WJ, Harmsen WS, Zinsmeister AR, Jewell DA, Sandborn WJ. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91–6.PubMedPubMedCentralCrossRef
85.
Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis:a meta-analysis. Gastrointest Endosc. 2002;56:48–54.PubMedCrossRef
86.
Kornfeld D, Ekbom A, Ihre T. Is there an excess risk for colorectal cancer in patients with ulcerative colitis and concomitant primary sclerosing cholangitis? A population based study. Gut. 1997;41:522–5.PubMedPubMedCentralCrossRef
87.
Sokol H, Cosnes J, Chazouilleres O, Beaugerie L, Tiret E, Poupon R, Seksik P. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol. 2008;14:3497–503.PubMedPubMedCentralCrossRef
88.
Thackeray EW, Charatcharoenwitthaya P, Elfaki D, Sinakos E, Lindor KD. Colon neoplasms develop early in the course of inflammatory bowel disease and primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2011;9:52–6.PubMedCrossRef
89.
90.
Lindström L, Lapidus A, Ost Å, Bergquist A. Increased risk of colorectal cancer and dysplasia in patients with Crohn’s colitis and primary sclerosing cholangitis. Dis Colon Rectum. 2011;54((11):1392–7.PubMedCrossRef
91.
Broden B, Halliday J, Aryasingha S, Sharifi Y, Checchin D, Warren BF, et al. Risk for colorectal neoplasia in patients with colonic Crohn’s disease and concomitant primary sclerosing cholangitis. Clin Gastroenterol Hepatol. 2012;10((3):303–8.CrossRef
92.
Korelitz BI, Lauwers GY, Sommers SC. Rectal mucosal dysplasia in Crohn’s disease. Gut. 1990;12:1382–6.CrossRef
93.
Igarashi T, Akimoto S, Otasiro Y, Hanyu F, Nagasako K. Precancerous lesions of the colon and rectum. Gan Kagaku Ryoho. 1989;16:1639–44.
94.
Richards ME, Rickert RR, Nance FC. Crohn’s diseaseassociated carcinoma. A poorly recognized complication of inflammatory bowel disease. Ann Surg. 1989;209:764–73.PubMedPubMedCentralCrossRef
95.
Petras RE, Mir-Madjlessi SH, Farmer RG. Crohn’s disease and intestinal carcinoma:a report of 11 cases with emphasis on associated epithelial dysplasia. Gastroenterology. 1987;93:1307–14.PubMedCrossRef
96.
Rutter MD, Saunders BP, Wilkinson KH, et al. Most dysplasia in ulcerative colitis is visible at colonoscopy. Gastrointest Endosc. 2004;60:334–9.PubMedCrossRef
97.
Engelsgjerd M, Farraye FA, Odze RD. Polypectomy may be adequate treatment for adenoma-like dysplastic lesions in chronic ulcerative colitis. Gastroenterology. 1999;117:1288–94, discussion 1488–1491.PubMedCrossRef
98.
Odze RD, Farraye FA, Hecht JL, et al. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol. 2004;2:534–41.PubMedCrossRef
99.
Rubin PH, Friedman S, Harpaz N, et al. Colonoscopic polypectomy in chronic colitis: conservative management after endoscopic resection of dysplastic polyps. Gastroenterology. 1999;117:1295–300.PubMedCrossRef
100.
Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003;124:544–60.PubMedCrossRef
101.
Kiran RP, Khoury W, Church JM, Lavery IC, Fazio VW, Remzi FH. Colorectal cancer complicating inflammatory bowel disease: similarities and differences between Crohn’s disease and ulcerative colitis based on three decades of experience. Ann Surg. 2010;252(2010):330–5.PubMedCrossRef
102.
Rieder F, Bruyn JR de, Pham BT, Katsanos K, Annese V, Higgins PD, Magro F, Dotan I. Results of the 4th scientific workshop of the ECCO (Group II): markers of intestinal fibrosis in inflammatory bowel disease. J Crohns Colitis. 2014;1;8(10):1166–78, Oct.CrossRef
103.
Rieder F, Latella G, Magro F, et al. European Crohn’s and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn’s Disease. J Crohns Colitis. doi:10.​1093/​ecco-jcc/​jjw055.
104.
Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-update based on new evidence. Gastroenterology. 2003;124:544–60.PubMedCrossRef
105.
Pellino G, Selvaggi F. From colon-sparing techniques to pelvic ileal pouch: history and evolution of surgery for ulcerative colitis. Eur Surg. 2015;47:81–90.CrossRef
106.
McLeod RS, Baxter NN. Quality of life of patients with inflammatory bowel disease after surgery. World J Surg. 1998;22:375–81.PubMedCrossRef
107.
Seidel SA, Newman M, Sharp KW. Ileoanal pouch versus ileostomy: is therea difference in quality of life? Am Surg. 2000;66:540–6.PubMed
108.
Feroci F, Lenzi E, Baraghini M, Cantafio S, Scatizzi M. General surgeons’ views on Oncologic Multidisciplinary Group meetings as part of colorectal cancer care. Updates Surg. 2012;64(4):273–8.PubMedCrossRef
109.
Wibe A, Syse A, Andersen E, Tretli S, Myrvold HE, Soreide O. Oncological outcomes after total mesorectal excision for cure for cancer of the lower rectum: anterior vs. abdominoperineal resection. Dis Colon Rectum. 2004;47:48–58.PubMedCrossRef
110.
Schroen AT, Cress RD. Use of surgical procedures and adjuvant therapy in rectal cancer treatment:a population-based study. Ann Surg. 2001;234:641–51.PubMedPubMedCentralCrossRef
111.
Selvaggi F, Fucini C, Pellino G, Sciaudone G, Maretto I, Mondi I, Bartolini N, Caminati F, Pucciarelli S. Outcome and prognostic factors of local recurrent rectal cancer:a pooled analysis of 150 patients. Tech Coloproctol. 2015;19:135–44.PubMedCrossRef
112.
Frykholm GJ, Glimelius B, Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: final treatment results ofa randomized trial and an evaluation of late secondary effects. Dis Colon Rectum. 1993;36:564–72.PubMedCrossRef
113.
Glimelius B, Gronberg H, Jarhult J, Wallgren A, Cavallin-Stahl E. A systematic overview of radiation therapy effects in rectal cancer. Acta Oncol. 2003;42:476–92.PubMedCrossRef
114.
Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T, Rutten HJ, Pahlman L, Glimelius B, Krieken JH van, Leer JW, Velde CJ van de. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med. 2001;345:638–46.PubMedCrossRef
115.
Snelgrove R, Brown CJ, O’Connor BI, Huang H, Victor JC, et al. Proctocolectomy for colorectal cancer – is the ileal pouch anal anastomosisa safe alternative to permanent ileostomy? Int J Colorectal Dis. 2014;29:1485–91.PubMedCrossRef
116.
Merchea A, Wolff BG, Dozois EJ, Abdelsattar ZM, Harmsen WS, Larson DW. Clinical features and oncologic outcomes in patients with rectal cancer and ulcerative colitis:a single-institution experience. Dis Colon Rectum. 2012;55:881–5.PubMedCrossRef
117.
Gorfine SR, Harris MT, Bub DS, Bauer JJ. Restorative proctocolectomy for ulcerative colitis complicated by colorectal cancer. Dis Colon Rectum. 2004;47:1377–85.PubMedCrossRef
118.
Radice E, Nelson H, Devine RM, Dozois RR, Nivatvongs S, Pemberton JH, Wolff BG, Fozard BJ, Ilstrup D. Ileal pouchanal anastomosis in patients with colorectal cancer: long-term functional and oncologic outcomes. Dis Colon Rectum. 1998;41:11–7.PubMedCrossRef
119.
Pellino G, Selvaggi F. Outcomes of Salvage Surgery for Ileal Pouch Complications and Dysfunctions. The Experience ofa Referral Centre and Review of Literature. J Crohns Colitis. doi:10.​1093/​ecco-jcc/​jjv066.
120.
Pellino G, Sciaudone G, Candilio G, De Fatico GS, Landino I, Canonico S, Selvaggi F. Restorative proctocolectomy with ileal pouch-anal anastomosis is safe and effective in selected very elderly patients suffering from ulcerative colitis. Int J Surg. 2014;12(Suppl 2):S56–9.PubMed
121.
Pellino G, Sciaudone G, Miele E, Candilio G, De Fatico GS, Riegler G, Staiano A, Canonico S, Selvaggi F. Functional outcomes and quality of life after restorative proctocolectomy in paediatric patients:a case-control study. Gastroenterol Res Pract. 2014;2014:340341 doi:10.​1155/​2014/​340341.PubMedPubMedCentralCrossRef
122.
Selvaggi F, Pellino G, Canonico S, Sciaudone G. Is omitting pouchography before ileostomy takedown safe after negative clinical examination in asymptomatic patients with pelvic ileal pouch? An observational study. Tech Coloproctol. 2012;16:415–20.PubMedCrossRef
123.
124.
Greenstein AJ. Cancer in inflammatory bowel disease. Mt Sinai J Med. 2000;67:227–40.PubMed
125.
Fornaro R, Secco GB, Picori E, Stabilini C, Frascio M, Ricci B, Mandolino F, De Salvo L, Gianetta E. Surgical treatment of Crohn’s disease complications. Our experience. G Chir. 2006;27:21–6.PubMed
126.
Fornaro R, Frascio M, Stabilini C, Sticchi C, Barberis A, Denegri A, Ricci B, Mandolino F, Lazzara F, Gianetta E. Crohn’s disease surgery: problems of postoperative recurrence. Chir Ital. 2008;60:761–81.PubMed
127.
Fornaro R, Frascio M, Denegri A, Stabilini C, Imperatore M, Mandolino F, Lazzara F, Gianetta E. Crohn’s disease and cancer. Ann Ital Chir. 2009;80:119–25.PubMed
128.
Selvaggi F, Sciaudone G, Limongelli P, Di Stazio C, Guadagni I, Pellino G, De Rosa M, Riegler G. The effect of pelvic septic complications on function and quality of life after ileal pouch-anal anastomosis:a single center experience. Am Surg. 2010;76:428–35.PubMed
129.
Pellino G, Sciaudone G, Selvaggi F, Riegler G. Delayed diagnosis is influenced by the clinical pattern of Crohn’s disease and affects treatment outcomes and quality of life in the long term:a cross-sectional study of 361 patients in Southern Italy. Eur J Gastroenterol Hepatol. 2015;27:175–8.PubMedCrossRef
130.
Pellino G, Selvaggi F, Ghezzi G, Corona D, Riegler G, Delaini GG. A think tank of the Italian society of colorectal surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: Crohn’s disease. Tech Coloproctol. 2015;19(10):639–51. doi:10.​1007/​s10151-015-1368-4.PubMedCrossRef
131.
Selvaggi F, Pellino G, Ghezzi G, Corona D, Riegler G, Delaini GG. A think tank of the Italian Society of Colorectal Surgery (SICCR) on the surgical treatment of inflammatory bowel disease using the Delphi method: ulcerative colitis. Tech Coloproctol. 2015;19(10):627–38. doi:10.​1007/​s10151-015-1367-5.PubMedCrossRef
132.
Cacciola NA, Calabrese C, Malapelle U, et al. UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients. Mol Carcinog. 2015;27 doi:10.​1002/​mc.​22322.
133.
Riegler G, Bossa F, Caserta L, Pera A, Tonelli F, Sturniolo GC, Oliva L, Contessini Avesani E, Poggioli G, IG-IBD Group. Colorectal cancer and high grade dysplasia complicating ulcerative colitis in Italy. A retrospective co-operative IG-IBD study. Dig Liver Dis. 2003;35:628–34.PubMedCrossRef
Metadaten
Titel
Large bowel cancer in the setting of inflammatory bowel disease
Features and management with a focus on rectal cancer
verfasst von
Gianluca Pellino, MD
Rosa Marcellinaro, MD
Guido Sciaudone, MD
Alfonso Reginelli, MD PhD
Pasquale Esposito, MD
Gabriele Riegler, MD
Silvestro Canonico, MD
Vincenzo Villanacci, MD
Francesco Selvaggi, MD
Publikationsdatum
01.08.2016
Verlag
Springer Vienna
Erschienen in
European Surgery / Ausgabe 4/2016
Print ISSN: 1682-8631
Elektronische ISSN: 1682-4016
DOI
https://doi.org/10.1007/s10353-016-0434-0

Weitere Artikel der Ausgabe 4/2016

Treatment of Boerhaave’s Syndrome: Specialized Esophago-Gastric Unit Experience on Twelve Patients

  • case report

Simultaneous resection of primary colorectal cancer and synchronous liver metastases is associated with a high cardiovascular complication rate

  • Original Article

Clinical and inflammatory response to first ileocolic resection for Crohn’s disease

  • original article

Retrospective analysis of prognostic factors in patients with duodenal adenocarcinoma

  • Original Article

The cleft lift procedure for complex pilonidal disease

  • short communication

Current strategies for preoperative conditioning of the liver to expand criteria for resectability of hepatic metastases

  • Review